Sobi receives positive CHMP opinion for Kineret® for treatment of rare disease CAPS
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the Committee forMedicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)has adopted a positive opinion for the use of Kineret for the treatment ofpatients with Cryopyrin-Associated Periodic Syndromes (CAPS).The opinion is based on a positive benefit risk assessment of the results from along-term treatment study in children and adults with NOMID/CINCA, the mostsevere form of CAPS. "We look forward to final decision from the European Commission in the comingmonths", said Birgitte Volck, Senior Vice